Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 14/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 8/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474581 | 0.92 | ULK1 (0.68) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL1474822 | 0.91 | ULK1 (0.61) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL1473849 | 0.90 | BRD4 (0.51) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL17547502 | 0.88 | PTK2B (0.72) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL19639657 | 0.88 | ULK1 (0.72) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL1474483 | 0.87 | INSR (0.50) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL1476601 | 0.87 | ULK1 (0.68) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL17545058 | 0.87 | PTK2B (0.82) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL29575705 | 0.87 | PTK2B (0.82) | ULK1PTK2BPTK2CDK1CCNB1 | |
| SCHEMBL17547520 | 0.83 | ULK1 (0.71) | ULK1PTK2BPTK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | claimed |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9593082-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-7915273-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008079907-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | ULK1 705/4885PTK2B 181/4885PTK2 468/4885 |
| US-20170121291-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ULK1 705/4885PTK2B 181/4885PTK2 468/4885 |
| US-20190256476-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ULK1 705/4885PTK2B 181/4885PTK2 468/4885 |
| US-20070203161-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ULK1 705/4885PTK2B 181/4885PTK2 468/4885 |
| US-20080221089-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | ULK1 737/4885PTK2B 579/4885PTK2 701/4885 |
| US-20100152218-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | ULK1 705/4885PTK2B 181/4885PTK2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.